$Aslan Pharmaceuticals(ASLN.US)$Anticipated upcoming milestones •Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
Aslan Pharmaceuticals股票讨论区
5 分钟前,美国东部时间上午 7:30
通过环球新闻专线
亚斯兰制药(纳斯达克股票代码:ASLN)是一家临床阶段、专注于免疫学的生物制药公司,致力于为患者开发创新疗法。该公司在加利福尼亚州圣地亚哥举行的2024年美国胸科学会(ATS)国际会议上宣布了一份重要的最新海报演讲...
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
暂无评论